Bausch & Lomb Incorporated
Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.
Inclusion Criteria: * Documented diagnosis of dry eye disease * Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis Exclusion Criteria: * Any active ocular disease * Anticipated wearing of contact lenses during study Additional criteria per protocol
BL1107 topical ocular solution
Verify or correct the compensation shown for this listing.